Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Agile Therapeutics completes phase III program for contraceptive patch

Jan. 3, 2012

Enrollment in phase II KRN-321 study begins in Japan

Jan. 3, 2012

Cardiolynx patents new pioglitazone derivatives

Jan. 3, 2012

Takeda identifies benzazepine derivatives for treatment of obesity

Jan. 3, 2012

Toray divulges new inhibitors of 11-beta-HSD1

Jan. 2, 2012

Alexion Pharmaceuticals announces planned acquistion

Dec. 30, 2011

PMI inhibitor improves N-glycosylation in model of glycolytic disorders

Dec. 30, 2011

Noven Pharmaceuticals reports phase III data on low-dose paroxetine mesilate

Dec. 29, 2011

Prosidion claims novel GPR119 receptor agonists/DPP IV inhibitors

Dec. 29, 2011

New inhibitors of sclerostin prepared in Hong Kong

Dec. 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...